DelveInsight’s “Muscle Invasive Bladder Cancer (MIBC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Muscle Invasive Bladder Cancer Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Muscle Invasive Bladder Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Muscle Invasive Bladder Cancer (MIBC): An Overview
Urothelial Carcinoma starts when cells that make up the urinary bladder become cancerous. Bladder neoplasms can arise from any of the four bladder wall layers. They are broadly classified as either epithelial or non-epithelial (mesenchymal), with over 95% being epithelial.
From a clinical point of view, urinary bladder cancers are classified as non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), because the invasion of the muscle layer is the major determinant of carrying out a cystectomy.
Muscle Invasive Bladder Cancer Market Key Facts
-
As per the National Cancer Institute, a high increase in the number of cases of UC, with an estimated number of 80,470 newly diagnosed cases and 17,670 deaths, was expected in 2019 in the United States.
-
As per Delveinsight, around 50,632 and 21,700 cases for NMIBC and MIBC, respectively occurred in 2017 in the United States.
-
The total incident population of Urothelial Carcinoma in the seven major markets was found to be 243,151 cases in 2017.
-
Among EU5 countries, Germany had the maximum total cases of locally advanced/metastatic Urothelial Carcinoma with 15,192 cases in 2017.
Muscle Invasive Bladder Cancer (MIBC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Muscle Invasive Bladder Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Muscle Invasive Bladder Cancer market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Muscle Invasive Bladder Cancer (MIBC) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Muscle Invasive Bladder Cancer (MIBC) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Muscle Invasive Bladder Cancer market or expected to get launched during the study period. The analysis covers Muscle Invasive Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Muscle Invasive Bladder Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-market
Muscle Invasive Bladder Cancer (MIBC) Therapeutics Analysis
The treatment protocols used for MIBC or Urothelial Carcinoma include chemotherapy, immunotherapy, radiation therapy, target-specific therapy, and surgical treatment. Metastatic urothelial carcinoma has shown poor survival when treated with chemotherapy; however, companies are working on developing new immunotherapies for the treatment of Muscle Invasive Bladder Cancer (MIBC).
Globally, there are approx. 30+ key companies which are developing therapies for Non-Muscle Invasive Bladder Cancer. Currently, UroGen Pharma has its Non-Muscle Invasive Bladder Cancer drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Muscle Invasive Bladder Cancer (MIBC) market include:
Merck, Bristol-Myers Squibb, Genentech, AstraZeneca, Janssen, UroGen Pharma, Astellas Pharma, Rexahn Pharmaceuticals, Immunomedics, Nektar Therapeutics, Acerta Pharma, Infinity Pharma, QED Therapeutics, Seattle Genetics, CG Oncology, Sasanlimab, Sesen Bio, Theralase Technologies, Asieris Pharmaceuticals, Hamlet Pharma, Viralytics, ImmunityBio, Prokarium, Vaxiion Therapeutics, Janssen Pharmaceuticals, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Incyte Corporation, Taizhou Hanzhong biomedical, and many others.
Muscle Invasive Bladder Cancer (MIBC) Therapies covered in the report include:
• Sacituzumab govitecan (IMMU-132)
• Bempegaldesleukin (NKTR-214)
• RX-3117
• ACP-196
• IPI-549
• Linrodostat (BMS-986205)
• Infigratinib
And many others.
Get More Detailed Insights Into the Emerging Therapies & Key Companies –
https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Muscle Invasive Bladder Cancer Competitive Intelligence Analysis
4. Muscle Invasive Bladder Cancer Market Overview at a Glance
5. Muscle Invasive Bladder Cancer Disease Background and Overview
6. Muscle Invasive Bladder Cancer Patient Journey
7. Muscle Invasive Bladder Cancer Epidemiology and Patient Population
8. Muscle Invasive Bladder Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Muscle Invasive Bladder Cancer Unmet Needs
10. Key Endpoints of Muscle Invasive Bladder Cancer Treatment
11. Muscle Invasive Bladder Cancer Marketed Products
12. Muscle Invasive Bladder Cancer Emerging Therapies
13. Muscle Invasive Bladder Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Muscle Invasive Bladder Cancer Market Outlook (7 major markets)
16. Muscle Invasive Bladder Cancer Access and Reimbursement Overview
17. KOL Views on the Muscle Invasive Bladder Cancer Market.
18. Muscle Invasive Bladder Cancer Market Drivers
19. Muscle Invasive Bladder Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Minimal Residual Disease Market
“Minimal Residual Disease Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Minimal Residual Disease Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/